Revolutionizing Disease Diagnosis and Treatment through Immuno-Biotechnologies: An Insight into Adaptive Biotechnologies Corporation’s Groundbreaking Platform and Upcoming Business Update

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is dedicated to revolutionizing disease diagnosis and treatment through the harnessing of the adaptive immune system’s biology. The company believes that this powerful tool has not been fully utilized due to challenges in decoding it. With its immune medicine platform, Adaptive Biotechnologies enables the decoding of adaptive immune system genetics with scale, precision, and speed.

The company collaborates with biopharmaceutical companies and informs drug development while developing clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Its products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with the goal of developing personalized immune-driven clinical products for each patient.

On Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, Adaptive Biotechnologies will host a business update conference call and webcast to provide investors with an update on its progress. The live audio of the webcast will be available on the “Investors” section of the company website at www.adaptivebiotech.com. The webcast will also be archived for replay within 24 hours after the event.

For inquiries from investors, Karina Calzadilla, Vice President of Investor Relations can be reached at investors@adaptivebiotech.com

Leave a Reply